Skip to main content
TipRanks
Go Ultimate75% OFF

60 Degrees Pharmaceuticals, Inc. (SXTP) Stock Price & Analysis

244 Followers

SXTP Stock Chart & Stats

$0.47-$0.03(-6.40%)
At close: 4:00 PM EST
$0.5$0.75$1$1.25Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$0.46 - $0.50
52-Week Range
$0.46 - $8.62
Previous Close
$0.50
Volume
N/A
Average Volume (3M)
677.36K
Market Cap
$2.24M
Enterprise Value
$13.06M
Total Cash (Recent Filing)
$306.19K
Total Debt (Recent Filing)
$208.50K
Price to Earnings (P/E)
―
Beta
1.77
Next Earnings
Mar 26, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Existing Commercial Product

ARAKODA gives the company an existing commercial product and an established malaria-focused platform rather than a portfolio consisting solely of unapproved candidates. Its measurable revenue and gross profit can support commercial learning while the company pursues additional indications.

Babesiosis Clinical Evidence

The expanded-access results provide clinically relevant evidence supporting tafenoquine in relapsing babesiosis, including molecular results consistent with cure in most assessed patients. If reinforced by the randomized study, this evidence could strengthen the regulatory case and expand the product opportunity.

Low Current Debt

Current debt is low and leverage is moderate, which limits near-term interest and repayment pressure relative to a more heavily indebted structure. This gives management some balance-sheet flexibility to direct available resources toward development and commercialization, despite broader capital constraints.

Bears Say

Small, Declining Revenue Base

Revenue remains too small to support the company’s cost structure, while the latest decline indicates that commercial traction is not yet consistently expanding. Deep operating and net losses leave the business dependent on future product growth, successful development, or additional financing.

Persistent Cash Burn

Cash outflows are many times larger than current revenue and closely track reported losses, showing that the funding requirement reflects recurring operating economics rather than mainly non-cash charges. Continued development and operations therefore depend on securing capital or materially improving cash generation.

Nasdaq Delisting Risk

The delisting decision creates a significant structural risk for the company’s market access and financing capacity over the next several months. Although a hearing is pending, the prior reverse splits and failure to qualify for another compliance period make the listing outcome an important execution overhang.

60 Degrees Pharmaceuticals, Inc. News

SXTP FAQ

What was 60 Degrees Pharmaceuticals, Inc.’s price range in the past 12 months?
60 Degrees Pharmaceuticals, Inc. lowest stock price was $0.46 and its highest was $8.62 in the past 12 months.
What is 60 Degrees Pharmaceuticals, Inc.’s market cap?
60 Degrees Pharmaceuticals, Inc.’s market cap is $2.24M.
When is 60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were 60 Degrees Pharmaceuticals, Inc.’s earnings last quarter?
60 Degrees Pharmaceuticals, Inc. released its earnings results on Nov 12, 2026. The company reported -$0.755 earnings per share for the quarter, missing the consensus estimate of -$0.61 by -$0.145.
Is 60 Degrees Pharmaceuticals, Inc. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does 60 Degrees Pharmaceuticals, Inc. pay dividends?
60 Degrees Pharmaceuticals, Inc. does not currently pay dividends.
What is 60 Degrees Pharmaceuticals, Inc.’s EPS estimate?
60 Degrees Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 60 Degrees Pharmaceuticals, Inc. have?
60 Degrees Pharmaceuticals, Inc. has 4,484,622 shares outstanding.
What happened to 60 Degrees Pharmaceuticals, Inc.’s price movement after its last earnings report?
60 Degrees Pharmaceuticals, Inc. reported an EPS of -$0.755 in its last earnings report, missing expectations of -$0.61. Following the earnings report the stock price went down -0.385%.
Which hedge fund is a major shareholder of 60 Degrees Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in SXTP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology